Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1669b ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Prurigo, Eosinophilic Esophagitis.
Abstract (Originalsprache)
The FDA has approved the subcutaneously injected interleukin (IL)-4 receptor alpha antagonist dupilumab (Dupixent – Sanofi/Regeneron) for treatment of eosinophilic esophagitis (EoE) in patients ≥12 years old who weigh ≥40 kg and treatment of prurigo nodularis in adults.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2023). Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1669b
Vancouver
Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1669b
BibTeX
@article{euvimed2023,
title = {Dupilumab (Dupixent) for Eosinophilic Esophagitis and Prurigo Nodularis},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1669b}
}
EUVIMED